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ABSTRACT
Liver receptor homologue 1 (LRH-1) is an orphan nu-
clear receptor that has been implicated in the pro-
gression of breast, pancreatic and colorectal cancer
(CRC). To determine mechanisms underlying growth
promotion by LRH-1 in CRC, we undertook global ex-
pression profiling following siRNA-mediated LRH-1
knockdown in HCT116 cells, which require LRH-1 for
growth and in HT29 cells, in which LRH-1 does not
regulate growth. Interestingly, expression of the cell
cycle inhibitor p21 (CDKN1A) was regulated by LRH-
1 in HCT116 cells. p21 regulation was not observed
in HT29 cells, where p53 is mutated. p53 dependence
for the regulation of p21 by LRH-1 was confirmed by
p53 knockdown with siRNA, while LRH-1-regulation
of p21 was not evident in HCT116 cells where p53 had
been deleted. We demonstrate that LRH-1-mediated
p21 regulation in HCT116 cells does not involve al-
tered p53 protein or phosphorylation, and we show
that LRH-1 inhibits p53 recruitment to the p21 pro-
moter, likely through a mechanism involving chro-
matin remodelling. Our study suggests an important
role for LRH-1 in the growth of CRC cells that retain
wild-type p53.
INTRODUCTION
Colorectal cancer (CRC) is one of the most commonly di-
agnosed cancers worldwide (1). Although five-year survival
rates over the last 40 years have greatly improved in many
countries, CRC remains the second most common global
cause of cancer deaths. CRC development occurs sequen-
tially through the accumulation of genetic changes or mu-
tations, resulting in unrestrained cellular proliferation and
survival (2,3). The genetic changes leading to CRC are well
defined, with aberrant activation of the Wnt/-catenin sig-
nalling pathway and loss of the tumour suppressor p53 be-
ing especially important.
Liver receptor homologue 1 (LRH-1; also known as
NR5A2) is a member of the NR5A, or Ftz-F1, sub-family
of nuclear receptors (NRs) (4). LRH-1 is expressed in tis-
sues of endodermal origin, including the intestine, pan-
creas, liver, ovaries and testes, as well as the adrenal gland
and placenta (4–9). The Ftz-F1 sub-family feature a re-
gion known as the Ftz-F1 box, a 26aa motif located C-
terminal to the DNA binding domain (DBD). NRs con-
taining this region are able to bind to a 9 bp DNA consen-
sus sequence, 5′-YCAAGGYCR-3′ (where Y is any pyrimi-
dine and R is any purine) as monomers (4,10). While there
is evidence that LRH-1 activity is regulated by binding of
phospholipids in the ligand binding domain (LBD) (11–
14), it is generally classed as an orphan NR. The LRH-
1 LBD is held in a permanently active conformation (15),
and its activity is primarily regulated by transcriptional
co-activators, such as peroxisome proliferator-activated re-
ceptor  coactivator-1 (PGC-1), and co-repressors, such
as the atypical NR small heterodimer partner (SHP; also
known as NR0B2) (16,17). Homozygous deletion of LRH-
1 is embryonic lethal at day E6.5 in mice, demonstrating
its importance in development (18,19), and LRH-1 regu-
lates the expression of octamer binding transcription fac-
tor 4 (Oct4), a transcription factor required for the mainte-
nance of pluripotency in embryonic stem cells (18). Strik-
ingly, LRH-1 can substitute for Oct4 in the reprogramming
of murine somatic cells to induced pluripotent stem cells
through regulation ofNanog, an important factor formain-
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taining pluripotency (20). Roles for LRH-1 have also been
established in the regulation of bile acid and cholesterol
homeostasis in the liver (4,21), in steroid hormone biosyn-
thesis in the ovary (22), and in the maintenance of preg-
nancy (23).
LRH-1 has also been implicated in cancer develop-
ment. Genome wide association studies have shown a link
between LRH-1 and pancreatic cancer (24), and down-
regulation of LRH-1 in pancreatic cancer cell lines inhibits
proliferation, thought to be due to reduced expression of c-
Myc and the cyclins D1 and E1 (25). LRH-1 expression is
frequently detected in breast tumours and surrounding adi-
pose tissue, and expression of LRH-1with estrogen receptor
 (ER) is positively associated in human breast carcinoma
tissues and in breast cancer cell lines (26–29). In breast can-
cer associated stroma, LRH-1 regulates expression of the
cytochrome P450 aromatase (CYP19) enzyme by binding
to promoter II of the CYP19 gene, thereby contributing to
the local biosynthesis of estrogen from 19 carbon steroids
(30,31). In breast cancer cells, LRH-1 expression is induced
by estrogen, via ER, and LRH-1 regulates breast cancer
cell growth (26,28). Regulation of growth involves direct
modulation of ER expression (28), stimulation of ER re-
cruitment toDNA, possibly by promoting co-factor recruit-
ment and remodelling of chromatin to a more open state
(32), and LRH-1 recruitment to regulatory regions of genes
that enhance cell growth (33). LRH-1 also promotes breast
cancer cell motility and invasion (34).
In the colon, LRH-1 has been implicated in intestinal
tumour formation. Mice heterozygous for an adenoma-
tous polyposis coli (APC) mutation and a LRH-1 inactivat-
ing mutation developed fewer intestinal tumours than mice
harbouring the APC mutation only, and LRH-1 heterozy-
gousmice developed fewer azoxymethane-induced aberrant
crypt foci (35). LRH-1 is highly expressed in the intestinal
crypts. In the crypts of mice heterozygous for LRH-1, re-
duced expression of cyclins D1 and E1, as well as reduced
DNA synthesis, has been described. Promotion of the pro-
liferation of intestinal cells by LRH-1 required synergism
with -catenin on the cyclin E1 and D1 gene promoters
(36). In CRC cells, LRH-1 also regulates the expression of
Cyp11A1 and Cyp11B1, steroidogenic enzymes that play
a key role in regulating levels of immunomodulatory glu-
cocorticoids, which act to suppress host immune responses
(37).
To further investigate the mechanisms of LRH-1 action
in CRC, we undertook gene expression microarray profil-
ing in two CRC cell lines following siRNA-mediated LRH-
1 knockdown to define the LRH-1 transcriptome. Pathway
analysis of differentially regulated genes identified an im-
portant role for LRH-1 in the regulation of the cell cycle in-
hibitor p21. Interestingly, regulation of p21 by LRH-1 was
dependent on p53 and was not observed if the p53 gene was
mutated or deleted. Collectively, this work demonstrates a
novel role for LRH-1 in the regulation of p21 levels in CRC
that retain wild-type p53, and identifies LRH-1 as a poten-
tial target for the treatment of these tumours.
MATERIALS AND METHODS
Cell culture
Cell lines were obtained from the American Tissue Type
Culture Collection and were maintained in the recom-
mended culture media. HCT116 p53−/− cells were kindly
provide by Dr. B. Vogelstein (38). HCT116 and HCT116
p53−/− cells were maintained in McCoy’s 5A medium.
HT29, LOVO and HCA46 cells were cultured in DMEM.
H1299 cells were maintained in RPMI-1640 medium. All
media were supplemented with 10% FCS.
Plasmids
The Renilla luciferase reporter gene plasmid was pRL-
CMV (Promega, UK). The p21 promoter firefly luciferase
reporter plasmid, p21-Luc has been described (39), as has
the p53 plasmid (40). HA-tagged LRH-1 (pCI-HA-LRH-
1) was generated from pCI-LRH-1 (13), as described (32).
pCI-HA-LRH-1 G95W was generated by site-directed mu-
tagenesis using the Quickchange kit (Stratagene, UK), us-
ing oligonucleotides having the sequence 5′-CCGTGTGT
GGAGATAAAGTGTCTTGGTACCATTATGG-3′.
Reporter gene assays
H1299 cells, seeded in 24-well plates, were transfected with
100 ng of p21-luc, 1 ng p53, 1–100 ng LRH-1 and 10 ng of
the renilla luciferase plasmid, pRL-CMV, using FuGENE
HD (Promega). Luciferase activities were determined after
24 h, using the Dual-Glo Luciferase Assay kit (Promega).
To control for transfection efficiency, firefly luciferase activ-
ities were calculated relative to Renilla luciferase activities.
siRNA transfections
Cells were transfected with double-stranded RNA
oligonucleotides to a final concentration of 5nM, us-
ing LipofectamineTM RNAiMAX (Invitrogen, UK) and
the reverse transfection method, according to man-
ufacturer’s instructions. ON-TARGETPlus siRNAs
for LRH-1 (Dharmacon, UK) have the sequences:
5′-AGAGAAAUUUGGACAGCUA-3′ (#1) and 5′-
GGAGUGAGCUCUUAAUCCU-3′ (#2). Silencer Select
siRNAs for TP53 (Ambion, UK) have the sequences:
5′-GUA AUC UAC UGG GAC GGA ATT-3′ (#1) and
5′-GAA AUU UGC GUG UGG AGU ATT-3′ (#2).
siLUC control (P-002099–01–20; Dharmacon) was used as
a negative control.
Cell proliferation assays
Cell growth was determined using the sulphorhodamine B
assay (SRB) (41). siRNA-transfected cells were seeded at a
density of 3 × 103 cells/well in 96-well plates. On the day
of measurement, cells were fixed by the addition of 100 l
ice-cold 40% trichloroacetic acid (TCA), followed by incu-
bation at 4◦C for 1 h. Cells were washed in ddH2O and
stained with 100 l 0.4% SRB dye in 1% acetic acid for 1
h. Cells were washed five times in 1% acetic acid and air
dried. Bound dye was solubilized by addition of 100 l of
10 mM Tris-base. Absorbance was read at 492 nm.
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Real-time quantitative polymerase chain reaction
RNA was collected using RNeasy Mini Preparation Kit
(QIAGEN, UK) according to the manufacturer’s instruc-
tions. cDNA was synthesized from 2 g RNA using
RevertAidTM M-MuLV reverse transcriptase (Fermentas,
UK). Obtained cDNA was diluted 1:10 and 2 l was used
in each PCR. Gene expression analyses were carried out us-
ing an Applied Biosystems 7900HT Fast Real-Time PCR
System with TaqMan R© gene expression assays (Applied
Biosystems, UK) for LRH-1 (Hs00892377 m1), CDKN1A
(Hs00355782 m1), TP53 (Hs01034249 m1) and GAPDH
(Hs99999905 m1).
Electrophoretic mobility shift assay (EMSA)
In vitro transcription of LRH-1 and LRH-1 G95W expres-
sion plasmids was performed with the T7 RNA polymerase
kit (Invitrogen). RNAwas in vitro translated using the Rab-
bit Reticulocyte Lysate System (Promega), according to
manufacturer’s instructions. EMSA was carried out as de-
scribed previously (32).
Western blotting
Whole cell lysates were prepared in radioimmune precipi-
tation (RIPA) buffer (Sigma-Aldrich), supplemented with
protease and phosphatase inhibitor cocktail tablets (Roche,
UK), and protein concentration was determined using
the Pierce BCA Protein Assay Kit (Thermo Fisher Scien-
tific, UK). Western blotting was performed using 20 g
of protein lysate, as previously described (42). Antibod-
ies for LRH-1 (ab41901), Bax (ab32503), p53-phospho-
ser15 (ab1431),Mdm2 (ab16895) and -actin (ab6276) were
purchased from Abcam, UK. p21 (sc-397) and p53 (sc-
126) were from Santa Cruz Biotechnologies, USA. p53-
phospho-ser33 (#2528), p53-phospho-ser392 (#9281) were
purchased from Cell Signaling, UK.
Co-immunoprecipitation (Co-IP)
Co-IPs were carried out using the ImmunoCruzTM IP/WB
Optima E System (Santa Cruz, UK), according to the man-
ufacturer’s instructions, with 1 mg whole cell lysate pre-
pared by RIPA extraction for each IP. 2 g of LRH-1 an-
tibody or normal mouse IgG (Invitrogen) was used per
IP. Following immunoprecipitation, samples were heated
at 100◦C for 3 min and 10 l of immunoprecipitated
complex was used for Western blotting. HRP conjugated
ImmunoCruzTM E antibody was used as the secondary an-
tibody.
Chromatin immunoprecipitation (ChIP)
For transient transfections, HCT116 cells seeded in 15 cm
dishes for 24 h were transfected with 5 g pcDNA vector
or pCI-HA-LRH-1 and 10 g BSM carrier DNA using Fu-
GENE HD. Lysates were prepared after 48 h. For siLRH-
1 ChIP analysis, cells were transfected with LRH-1 siRNA
and lysates were prepared 24 h after transfection.Where ap-
propriate, cells were treated with DMSO or 10 M etopo-
side for 24 h. ChIP was performed as previously described
(28,32). ChIP primers have also previously been described
(28,32,43). Antibodies for H3 (ab1791), H3K9Ac (ab4441),
H3K27Ac (ab4729), H3K4me3 (ab8580) and H3K9me3
(ab8898) were purchased from Abcam, UK.
Gene expression microarray analysis
HCT116 and HT29 cells were transfected with LRH-1
siRNA #1, #2 or with siLUC. Total RNA was prepared
24 h later using the RNeasy Mini Preparation Kit (QIA-
GEN). Following assessment of RNA integrity, four in-
dependent biological replicates for each siRNA treatment
were used for microarray analysis. The analysis was per-
formed using HumanHT-12 v4 Expression BeadChip (Illu-
mina, UK). The BeadChip image data were pre-processed
using GenomeStudio (Illumina). Raw data were filtered
prior to normalization to remove non-expressed probes (if
for a given probe the detection P-values for all samples
were >0.05 it was considered not expressed). The expres-
sion data were log2 transformed and quantile-normalized
using Partek Genomics Suite (Partek, USA). The microar-
ray data have been deposited with the NCBI Gene Expres-
sion Omnibus (GEO) (http://ncbi.nlm.nih.gov/geo/) under
accession number GSE65815. Pathway analyses were per-
formed using the database for annotation, visualization
and integrated discovery (DAVID; http://david.abcc.ncifcrf.
gov) (44,45).
RESULTS
Differential regulation of CRC cell growth by LRH-1
Given the described role of LRH-1 in CRC, we investigated
the importance of LRH-1 for CRC cell growth, follow-
ing siRNA-mediated knockdown in two commonly used
CRC cell lines, HCT116 andHT29. These lines were chosen
since they show moderate or high LRH-1 expression (Sup-
plementary Figure S1). Transfection with two independent
LRH-1 siRNAs in HCT116 resulted in significant reduc-
tion in LRH-1 at both the mRNA and protein levels, which
was accompanied by 85% (siLRH-1 #1) and 69% (siLRH-1
#2) growth inhibition relative to the control siRNA (siLUC)
(Figure 1A–C). Interestingly, these siRNAs failed to elicit
a substantial growth effect in HT29 cells (Figure 1D–F).
It should be noted that several LRH-1 isoforms arising
from alternative 5′ exon usage and/or alternative splicing
yield LRH-1 polypeptides that differ in molecular mass by
5–10 kDa (28). Immunoblotting shows a 55 kDa LRH-1
polypeptide present in all CRC cell lines, expected to corre-
spond to the 495aa LRH-1 variant. The larger 541aa vari-
ant 1 was absent in HCT116 cells.
Gene expression microarray analysis for the identification of
LRH-1 regulated genes in CRC cells
These results demonstrate a potential role for LRH-1 in the
regulation of HCT116 growth, but do not provide a func-
tion for LRH-1 in HT29 cells. To identify LRH-1-regulated
genes and to determine the possible mechanisms underly-
ing the differential role of LRH-1 on growth in these cell
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Figure 1. LRH-1 can regulate the growth of CRC cells. HCT116 and HT29 cells were transfected with two LRH-1 siRNAs. The non-targeting control
siRNA (siLUC) served as a control for transfection. (A,D) The growth of cells transfected with siRNA was measured by SRB assay. (B, E) RNA prepared
72 h post-transfection was used in qRT-PCR for LRH-1. LRH-1 expression was normalised to GAPDH levels and is shown relative to expression in siLUC
transfected controls. (C, F) Immunoblotting for LRH-1 and -actin was carried out using lysates prepared 72 h following siRNA transfection. Graphical
data show the means of three independent experiments, with error bars representing the SEM; * = P < 0.001.
lines, global gene expression profiling was undertaken fol-
lowing LRH-1 knockdown in both cell lines, using the Il-
lumina HumanHT-12 v4 Expression BeadChip. Four inde-
pendent RNA samples for each of the two LRH-1 siRNAs
were analysed, to facilitate robust statistical analysis of the
microarray data.
Hierarchical cluster analysis of HCT116 cells identi-
fied 597 probes, representing 576 genes, whose expression
was significantly altered (P-value with false discovery rate
(FDR)<0.05) by the LRH-1 siRNAs (Figure 2A). The gene
lists are provided in Supplementary Tables S1–S6. Expres-
sion of 225 (230 probes) of these genes, including LRH-1
(NR5A2), was significantly reduced, whilst a greater num-
ber, 351 genes (367 probes), were up-regulated following
LRH-1 knockdown, suggesting that gene repression by
LRH-1 is an important feature of its action inHCT116 cells.
In HT29 cells, 63% (272 of 435) of LRH-1-regulated genes
were up-regulated upon LRH-1 knockdown (Figure 2B),
similar to the proportion of the genes (61%) that were up-
regulated in HCT116 cells. Real-time RT-PCR analysis for
a selection of the identified genes confirmed regulation by
LRH-1 in the two cell lines (Supplementary Figure S2).
Comparison of the HCT116 expression profiles with
those of HT29 showed that only 25% (146 of 576) of the
LRH-1 regulated genes in HCT116 were also regulated in
HT29 cells (Figure 2C, Supplementary Tables S1–S6), in-
dicating that the greater part of LRH-1 function is distinct
in these cell lines. Pathway enrichment analysis allows the
identification of potential signalling pathways and aids in
the determination of the putative function of the molecule
of interest. To identify signalling pathways that may medi-
ate LRH-1 function in CRC, gene ontology (GO) analyses
were undertaken using the online tool DAVID (44,45). Sig-
nificant GO biological process groups for LRH-1-regulated
genes common to both cell lines were related to endoplas-
mic reticulum processes and protein transport (Figure 2D,
Supplementary Table S7). In HT29 cells, LRH-1-regulated
genes were especially enriched for processes implicated in
protein catabolism, modification, localization and trans-
port (Supplementary Table S7).
In addition to the regulation of protein metabolism, the
cell cycle emerged as themost significantGObiological pro-
cess for LRH-1-regulated genes identified in HCT116 cells.
This was confirmed in analysis of Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways in HCT116 cells,
which also included the terms ‘pathways in cancer’ and ‘p53
signalling pathway’ (Figure 2E).
LRH-1 action is associated with regulation of p21 expression
in HCT116 cells
Pathway analysis showed enrichment for cell cycle regula-
tion and p53 signalling in HCT116 cells where LRH-1 was
silenced. Interestingly, many of the genes associated with
the cell cycle, including CCNB1, CCNB2 and CCNE2 were
up-regulated upon LRH-1 knockdown in HCT116 cells
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Figure 2. Expression profiling shows that LRH-1 regulates the expression of cell cycle genes in HCT116 cells but not HT29 cells. (A, B) Gene expression
profiling was carried out using four independent replicates of HCT116 cells transfected with siLUC, siLRH-1 #1 or siLRH-1 #2. Shown are differentially
expressed genes at P < 0.05 corrected for FDR. (C) Venn diagram shows the overlap between genes that are differentially expressed upon silencing of
LRH-1 in HCT116 (orange) and genes that are differentially expressed upon silencing of LRH-1 in HT29 (blue). (D) Gene Ontology (GO) analysis of
genes that are LRH-1 regulated in HCT116 and in HT29 cells. (E) KEGG Pathway enrichment analysis for LRH-1 regulated genes in HCT116 are shown.
(Figure 3A). Given that LRH-1 knockdown inhibited the
growth of HCT116 cells, up-regulation of the p53-regulated
cell cycle inhibitor p21, encoded by theCDKN1A gene, was
especially interesting, since this suggests that promotion of
HCT116 cell growth by LRH-1 may involve repression of
p21 expression. Real-time RT-PCR and immunoblotting
confirmed that p21 is up-regulated followingLRH-1 knock-
down in HCT116 cells (Figure 3B–C). By contrast, there
was no increase in p21 mRNA or protein levels upon LRH-
1 knockdown in HT29 cells.
While HCT116 cells are wild-type for p53, HT29 cells
possess a mutant form of p53 in which arginine-273 is mu-
tated to histidine (R273H) (46). The R273H mutation is
classified as a ‘DNA contact’ mutation, which abolishes the
ability of p53 to activate transcription of its target genes,
including p21 (47,48). It might be hypothesized, therefore,
that LRH-1-mediated regulation of p21 occurs via p53, and
in HT29 cells, where p53 signalling is abrogated, LRH-1-
mediated regulation of p21 is absent. To establish if p53 is
indeed required for LRH-1-mediated growth of HCT116
cells, HCT116-p53−/− cells, which lack full-length p53 ex-
pression owing to homologous recombination-mediated
deletion (38), were transfected with LRH-1 siRNAs. Ex-
pression of p21 was not affected and growth was only
marginally reduced in the p53-null HCT116 cells (Fig-
ure 4A–C).
Knockdown of p53 in HCT116 cells resulted in robust
down-regulation of p21 protein expression (Figure 4D),
consistent with the fact that p53 is the major transcrip-
tional regulator of p21 (49). While p21 protein expression
was increased upon knockdown of LRH-1 only (Figure 4D,
E), LRH-1 siRNAs did not increase p21 expression when
co-transfected with si-p53.Moreover, although knockdown
of p53 did not significantly affect HCT116 cell growth, it
was able to rescue the inhibition of HCT116 cell growth by
siLRH-1 (Figure 4F).
Similar to our findings for HCT116 and HT29 cells,
LRH-1 knockdown inhibited the growth of LOVO cells,
which are wild-type for p53 (50), but did not affect growth
of HCA46 cells, which are p53 null (Supplementary Fig-
ure S3). Moreover, p21 expression was increased by LRH-1
siRNA in LOVO cells, but was unaffected in HCA46 cells,
showing that the p53-dependent modulation of p21 expres-
sion by LRH-1 is not restricted to HCT116 and HT29 cells.
Taken together, the above results show that p21 is an im-
portant target for LRH-1 in cells that express non-mutated
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Figure 3. The cyclin dependent kinase (CDK) inhibitor p21 is up-regulated in HCT116 cells following LRH-1 silencing. (A) Genes showing LRH-1
regulation in HCT116 that are identified in the KEGG category ‘cell cycle’; FC = fold change. (B) Real-time RT-PCR for LRH-1 and p21 (CDKN1A)
was performed in HCT116 and HT29 cells following transfection with LRH-1 siRNA. Gene expression was normalised to GAPDH and is shown relative
to expression for the control siRNA. The data are the means of six biological replicates and error bars represent the SEM. Statistical significance was
calculated by unpaired two-tailed t-test, *P < 0.0001. (C) Western blotting for LRH-1 and p21 following LRH-1 knockdown in HCT116 and HT29 cells.
p53. As p53 is the major transcriptional regulator of p21
(49), we next investigated if LRH-1 regulates the expres-
sion of p21 indirectly, via p53. Although gene expression
profiling in HCT116 cells did not provide any evidence
for the regulation of p53 by LRH-1 at the mRNA level,
it is possible that silencing of LRH-1 may result in accu-
mulation of p53 at the protein level. However, no changes
in p53 protein levels were observed following transfection
of HCT116 and HT29 cells with LRH-1 siRNAs (Fig-
ure 5). Stabilization and activation of p53 requires a se-
ries of post-translational modifications, and phosphoryla-
tion represents a key determinant of p53 activation. Serine-
15 and serine-33 of p53 are frequently phosphorylated in re-
sponse to genotoxic and non-genotoxic stresses, and serine-
15 phosphorylation represents a priming event for subse-
quent modifications (51). No phosphorylation of p53 at
serine-15, serine-33, or serine-392 was observed following
LRH-1 silencing in HCT116 cells (Figure 5), indicating that
p53 is not activated, at least through kinases that phospho-
rylate these residues. As expected, p53 levels and phospho-
rylation were stimulated by treatment with the DNA dam-
aging agent etoposide.
Bax, a direct transcriptional target of p53 and a key me-
diator of p53-dependent apoptosis (52) was increased for
siLRH-1 #2, but was unaffected by siLRH-1 #1. Levels of
Mdm2, another p53 target gene that is critical for p53 ac-
tivity, were also unaffected by LRH-1, indicating that inhi-
bition of p53 target gene expression is not a general feature
of LRH-1 activity in HCT116 cells.
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Figure 4. LRH-1 mediated growth inhibition in HCT116 cells requires p53. (A, C) HCT116 p53−/− cells were transfected with 5 nM siRNA for LRH-1
or siLUC. Real-time RT-PCR (A), Western blotting (B) and growth (C) are shown. (D–F) HCT116 cells were transfected with 5nM siRNA for LRH-1
and/or 5 nM siRNA for p53 and/or siLUC, to a final siRNA concentration of 10 nM. (D) Western blotting following transfection with siRNAs for p53
and/or LRH-1. (E) Real-time RT-PCR was performed to confirm knockdown of LRH-1 and p53. (F) Growth, as measured by SRB assay, at day five
post-transfection, relative to siLUC. Total RNA and protein were prepared 72 h post-transfection. Gene expression data are normalized to GAPDH, and
are relative to siLUC. Results shown are the mean of three independent experiments and error bars represent the SEM, * = P < 0.01.
Regulation of p21 expression by LRH-1 requires its recruit-
ment to the p21 gene promoter
As gene expression profiling and immunoblotting yielded
no evidence for LRH-1-mediated regulation of p53 expres-
sion or activity, we sought to determine if LRH-1 acts by
regulating p53 recruitment to the p21 gene promoter and/or
if it directly binds to the p21 promoter. Reporter gene assays
with a firefly luciferase gene containing the 2.4 kb promoter
region of p21 (39), were performed in p53-null H1299 cells.
Transfection of p53 alone potently activated p21-Luc. This
p53-mediated activation was inhibited by LRH-1 in a dose-
dependent manner (Figure 6A).
Large-scale sequencing projects are being undertaken for
the comprehensive cataloguing of genes that are mutated in
cancer. Searching the Catalogue of Somatic Mutations in
Cancer (COSMIC) database (53) highlights several muta-
tions in the LRH-1 gene in CRC. One of these mutations,
a G95W change in the LRH-1 DBD, might be expected to
have alteredDNAbinding. Indeed, this mutation prevented
binding of LRH-1 to known LRH-1 binding site sequences
from the TFF1 and NRIP1 genes (32), as well as the bind-
ing site in the AFP gene (54) (Supplementary Figure S4).
Although wild-type LRH-1 inhibited p53-mediated activa-
tion of p21-luc, no inhibition was observed following trans-
fection of the G95W mutant (Figure 6B), indicating that
DNAbinding is required for LRH-1-mediated repression of
p53 transactivation. Interestingly, we found no evidence for
direct interaction between LRH-1 and p53 in co-IPs (Fig-
ure 6C).
The reporter gene assays suggest that LRH-1 binds to the
p21 gene promoter to repress its expression. In ChIP assays,
p53 was bound to the p53-response element (p53RE) re-
gion of the p21 promoter, and etoposide addition stimulated
p53 binding (Figure 7A, B). Similar results were obtained
for the BAX promoter. Due to insufficient enrichment of
LRH-1 pull-down using commercially available antibodies
(32), ChIP for LRH-1 was performed using a HA antibody
following transfection of HA-LRH-1 into HCT116 cells.
ChIP for HA-LRH-1 demonstrated recruitment of LRH-
1 to the p21 promoter at both the p53RE and the tran-
scription start site (TSS) regions (Figure 7C). Enrichment
of LRH-1 was also observed at the SHP and NRIP1 pro-
moters, both of which are direct transcriptional targets of
LRH-1 (32,55). Immunoblotting confirmed the expression
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Figure 5. LRH-1 silencing results in up-regulation of p21, but not p53, in HCT116 cells. HCT116 and HT29 cells were transfected with 5nM LRH-1
siRNA or siLUC and protein lysates were prepared 72 h post-transfection. Untransfected HCT116 and HT29 cells were seeded, treated with DMSO or 10
M etoposide, and protein lysates were prepared after 24 h.
Figure 6. LRH-1 inhibits p53-mediated activation of the p21 promoter. (A) The p53-deficient H1299 cells were transfected with p21-Luc, p53, and in-
creasing amounts of LRH-1. p21-Luc activity was corrected for transfection efficiency by normalization to renilla luciferase activity. p21-luc activities are
shown relative to the activity for the vector control (n = 3). Statistical significance was calculated by unpaired two-tailed t-test: ****P < 0.0001, ***P <
0.001, **P < 0.01, *P < 0.05. (B) H1299 cells were transfected with p53, LRH-1 and the G95W LRH-1 mutant. Reporter gene activity was assessed as in
part A (n = 3; * P< 0.001). Western blotting confirmed expression of LRH-1 and p53. (C) HCT116 protein lysates were immunoprecipitated with LRH-1
antibody and immunoblotted for LRH-1 and p53. Input represents 25% of the total volume of lysate used in the immunoprecipitation.
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Figure 7. LRH-1 is recruited to the p21 promoter and LRH-1 knockdown enhances p53 recruitment to the p21 promoter. (A) HCT116 cells treated with
10 M etoposide for 24 h were fixed for ChIP for p53. p53 recruitment to the p53RE and TSS regions of the p21 promoter and to the BAX promoter was
assessed by qPCR. (B) Western blotting for HA-LRH-1 and p53 is also shown. (C) HA-LRH-1 transfected HCT116 cells were fixed and harvested after
24 h and ChIP was performed using a HA antibody. HA-LRH-1 recruitment to the p21, BAX, SHP and NRIP1 promoters was assessed by qPCR. (D)
HCT116 cells transfected with 5 nM siLRH-1 or siLUC were fixed and harvested 24 h post-transfection and p53 ChIP was performed. p53 recruitment
to the p21 and BAX gene promoters was determined by qPCR. Bar charts represent the mean of qPCR results obtained from three biological replicates,
presented as a percentage of the input DNA and error bars represent SEM. Statistical significance was calculated by unpaired two-tailed t-test: *P< 0.01,
n.s. = not significant. (E, F) HCT116 cells were transfected with control siRNA or with two siRNAs for LRH-1. ChIP of histone H3 at acetylation and
methylation sites is shown normalized to total H3. *P < 0.05. The data are representative of triplicate experiments, ±SEM. (G) Western blotting showing
levels of LRH-1, p21 and p53 proteins in the ChIP lysates.
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of HA-LRH-1 and the accumulation of p53 following treat-
ment of HCT116 cells with etoposide (Figure 7B).
Knockdown of LRH-1 promoted p53 recruitment to the
p21 promoter (Figure 7D), suggesting that LRH-1 prevents
p53 recruitment to the p21 gene promoter. LRH-1 knock-
down resulted in a marked decrease in levels of the repres-
sive histone H3 mark, H3K9Me3 (Figure 7E, F) and pro-
moted H3 modifications associated with gene activation,
specifically acetylation at H3K9, H3K27Ac and methyla-
tion of H3K4Me3, indicating that LRH-1 maintains the
p21 promoter in a transcriptionally repressive state and that
its loss results in chromatin remodelling, which facilitates
p21 expression through the action of p53. No significant
changes in p53 protein levels were observed (Figure 7G).
DISCUSSION
An important role for the orphan NR LRH-1 in the devel-
opment of breast, pancreatic and colon cancer has recently
emerged (4,56). In the colon, LRH-1 has been implicated in
cell cycle progression and tumourigenesis (35,36). In agree-
ment with work connecting LRH-1 to proliferation in CRC
(36), we observed inhibition of HCT116 CRC cell growth
following LRH-1 silencing, although the same was not seen
for HT29 cells. Global gene expression profiling provides
the means of identifying the potential function of LRH-1 in
these cells. We used two independent siRNAs for LRH-1 to
aid robust identification of LRH-1 regulated genes and per-
formedmicroarray analysis. This analysis identified 435 and
576 genes that were differentially regulated following LRH-
1 siRNA in HT29 and HCT116 cells, respectively. The high
numbers of genes identified are consistent with the role of
LRH-1 as a transcription factor (4). Only 146 genes were
shared between the two cell lines, indicating that LRH-1
regulates the expression of discrete sets of genes in the two
lines. It is possible that LRH-1 can regulate different subsets
of genes depending on the wider cellular context, i.e. chro-
mosomal instability (CIN), a feature of HT29 cells versus
microsatellite instability (MSI), a feature of HCT116 cells
(46).
LRH-1 plays key metabolic roles in the liver, including
the regulation of cholesterol and bile acid homeostasis (4)
and the regulation of glucose metabolism (57). The phos-
phatidylcholine transfer protein (PCTP) gene, involved in
phospholipid exchange (58), was stimulated significantly in
HCT116 following LRH-1 knockdown, while SLC10A3, a
putative bile acid transporter (59) was down-regulated in
HCT116. There was no clear evidence for LRH-1 regula-
tion of additional genes previously identified as LRH-1-
regulated in other tissues, which suggests that LRH-1 is not
extensively involved in these processes in CRC cells. Inter-
estingly, in line with previous findings (60), there was signifi-
cant enrichment in both cell lines for biological processes in-
cluding protein transport, localization and catabolism, thus
identifying a novel putative metabolic role for LRH-1 in the
intestine and in CRC that deserves detailed investigation.
Previous studies have shown that co-operativity between
LRH-1 and -catenin promotes intestinal cell proliferation,
and LRH-1 haploinsufficiency (Lrh+/−) in mice is associ-
atedwith reduced tumourigenesis in the colon (35). Interest-
ingly, the expression of a number of -catenin target genes
associated with cell proliferation, specifically the CCNB1,
CCNB2 andMYC genes (61,62), were modulated by LRH-
1, suggesting that these genes may be the key mediators of
the crosstalk between -catenin and LRH-1 in CRC. How-
ever, CCND1 and CCNE1, previously identified as targets
for co-operativity between LRH-1 and -catenin (25), were
not identified as LRH-1 target genes in our microarrays.
Bayrer et al. (60) showed recently that CCNE1 expression
is reduced upon shRNAmediated LRH-1 knockdown. The
authors found that, although CCNE1 expression was not
significantly reduced in HT29 cells, cell growth was mod-
estly reduced, in apparent contrast to our findings. While
the differences in our results with those of Bayrer et al. are
unclear, a role for LRH-1 in CRC cell growth is obvious.
Prominent among the genes identified in our microar-
ray analysis was p21, a key mediator of the p53 response
(39). p21 expression is induced by p53 in response to myr-
iad stress stimuli, uponwhich it binds to and inhibits CDKs,
blocking cell cycle progression at G1- and S-phases (63,64).
p53 regulation of p21 expression occurs via direct DNA
binding to two highly conserved p53 response elements in
the p21 promoter (39,49). siRNA studies confirmed that
LRH-1 regulates the expression of p21 in a p53-dependent
manner. Further, we show that LRH-1 inhibits p53 activ-
ity on the p21 gene promoter, likely through a mechanism
involving the regulation of p53 recruitment to the p53 bind-
ing region. Our results indicate that the effects mediated by
LRH-1 do not involvemodulation of p53 levels, nor do they
involve regulation of p53 activity by altered phosphoryla-
tion. Silencing of LRH-1 in HT29 cells did not result in up-
regulation of p21 or in inhibition of cell growth; these cells
possess a mutant, non-transcriptionally active form of p53
(46–48).
A mechanism to explain the modulation of p53 sig-
nalling by LRH-1 involves a form of transcriptional in-
terference, mediated through the concomitant recruitment
of one or more co-repressors to the p21 promoter (Fig-
ure 8). ChIP and reporter gene studies showed that LRH-1
is recruited to the p21 promoter region. Moreover, a LRH-
1 mutant defective for DNA binding did not inhibit p53-
mediated stimulation of the p21 reporter gene. Analysis of
the p21 promoter sequence included in the p21 reporter
gene identified potential LRH-1 binding sites at −2605
to −2597 (5′-TGAAGGTGA-3′) and −1208 to −1201 (5′-
GAAGTCCA-3′) bp, the latter overlapping with a site pre-
viously linked to regulation of p21 by retinoid receptors
(65). LRH-1-directed co-repressor recruitment could ex-
ert its influence on p53 by inhibiting p53 transactivation
and promoting dissociation of p53 from DNA. The NR
co-repressor SHP, which is bound preferentially by LRH-1
(13), interacts with LRH-1 onDNA and abolishes its trans-
activation ability (66,67). Interestingly, recent evidence sug-
gests that SHP can regulate levels of p53 by augmenting
the ubiquitination and degradation of p53 by Mdm2 (68).
However, as we have been unable to detect SHP mRNA ex-
pression in HCT116 cells (data not shown), it is unlikely
that SHP is the co-repressor responsible for this effect. Nor
did we observe LRH-1 dependent changes in p53 levels.
Other possibilities include the LRH-1 co-repressors SMRT
(69), Dax-1 (70) and Prox1 (71), or the NR co-repressor
NRIP1, which recruits transcriptional co-repressors of the
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Figure 8. A model for LRH-1-mediated modulation of wild-type p53 signalling at the p21 promoter. (A) Recruitment of LRH-1 and associated co-
repressors and HDACs to the p21 promoter results in inhibition of p53-mediated transactivation and dissociation of the tetramer from the DNA. This
may be facilitated in part through deacetylation of p53 by HDACs, resulting in inhibition of p21 transcription and cell cycle progression. (B) LRH-1
down-regulation eliminates its repressive effect on p53, allowing transcription of p21 and cell cycle inhibition. (C) In CRC cells harbouring mutant p53,
such as the HT29 cell line, p21 transcription is minimal, and recruitment of LRH-1 to the gene promoter has no further effect.
C-terminal binding protein (CtBP) family, as well as histone
deacetylases (HDACs) (72). LRH-1 knockdown resulted in
a reduction in levels of the transcription repressive histone
H3 modification at lysine-9 and an increase in H3 acety-
lation, indicating that regulation of p21 by LRH-1 does in-
deed involve the recruitment of transcriptional co-repressor
complexes to the p21 promoter. Additionally, a recent study
has identified p21 as a LRH-1 regulated gene in breast can-
cer cells (73), that involves an additional LRH-1 binding
region 62 kb upstream of the p21 gene.
In summary, we demonstrate the importance of LRH-1
in the regulation of CRC cell growth. We provide evidence
for modulation of p53 signalling at the p21 promoter, me-
diated by LRH-1, and propose a model in which LRH-1,
in complex with co-repressors, suppresses p53 action at the
p21 gene, allowing CRC cells to evade cell cycle arrest me-
diated by p21. The mutation or loss of p53 is known to be a
relatively late event in colorectal tumourigenesis and tends
to occur alongside the transition from benign to malignant
growth (74). Therefore, it is possible that prior to p53 muta-
tion, LRH-1 allows early adenomas to evade p53-mediated
cell cycle arrest induced by pre-malignant changes, such
as excessive Wnt pathway activation. The requirement for
LRH-1 in the growth of CRC harbouring wild-type p53
makes it a potential drug target, a possibility that undoubt-
edly warrants further investigation and one that should be-
come amenable to testing with small molecule selective in-
hibitors of LRH-1 that are actively being sought (75–77).
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